Allergan Inc (AGN) 159.70 $AGN
Allergan Earnings Review: 12 Days after Announcement Shares Down 3.5% (AGN)
Comtex SmarTrend(R) - 2 hrs 12 mins ago
When Allergan (AMEX:AGN) reported earnings a week ago on May 7th, 2014, analysts, on average, expected the company to report earnings of $1.12 on sales of $1.6 billion. The company actually reported EPS of $1.18 on sales of $1.6 billion, beating EPS estimates by $0.05 and beating revenue estimates by $40.0 million. Shares of Allergan have slipped from $165.83 to $160.00, representing a loss of 3.5%, since the company reported earnings 12 days ago.
Abbott to Buy CFR Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 19, 11:00AM CDT
In a move to broaden its presence in the Latin American market, Abbott Labs (ABT) announced that it has entered into a definitive agreement to acquire CFR Pharmaceuticals.
Global Hyaluronic Acid Products Market - Forecast to 2019: Allergan, Anika and Merz dominating
PR Newswire - Mon May 19, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d98v85/hyaluronic_acid) has announced the addition of the "Global Hyaluronic Acid Products Market - Forecast to 2019: Allergan, Anika and Merz dominating" report to their offering.
AstraZeneca Rejects Pfizer's Final Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 19, 10:07AM CDT
AstraZeneca (AZN) announced that it has rejected Pfizer's (PFE) latest takeover proposal.
Global Anti-Aging Product Market 2014-2018: Beiersdorf AG, L'Oreal, Phosphagenics, Procter & Gamble & Unilever Group Dominate the Market
M2 - Mon May 19, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76jcqj/global_antiaging) has announced the addition of the "Global Anti-Aging Product Market 2014-2018" report to their offering. The analysts forecast the Global Anti-aging Product market will grow at a CAGR of 6.7% over the period 2013-2018. One of the main drivers is the rising global aging population. This growth is resulting in an increase in the need for anti-aging and age-defying facial products. Consumers are increasingly using anti-aging products made from natural and organic ingredients. Over the years, consumers have started seeking safe products and are now paying more attention to the ingredients in the anti-aging products, preferring those that do not contain chemicals or ingredients that could cause harmful side effects. Typically, anti-aging skincare and hair care products are made from synthetic ingredients, additives, and fillers. Such products could harm skin and hair, or even weaken and loosen skin when it starts aging. Natural oils such as argan, marula, coconut, and almond are some popular ingredients used in organic products. As organic products have little harmful effects, many large companies are launching natural and organic products to gain more market share. Further, the report states that one of the main challenges hindering market growth is the intensifying competition in the market caused by the entrance of new players and private labels. Key Vendors - Beiersdorf AG - L'Or?al SA - Phosphagenics Ltd. - Procter & Gamble Co. - Unilever Group Other Prominent Vendors - Allergan Inc. - Amexdrug Corp. - Avon Products Inc. - Chanel SA - Christian Dior SA - Clarins USA Inc. - DS Healthcare Group Inc. - Elizabeth Arden Inc. - Ella Bach? - Est?e Lauder Co. Inc. - Henkel AG & Co KGaA - Jan Marini Skin Research Inc. - Johnson & Johnson Co. - Kao Corp. - NeoStrata Co. - NuSKin Enterprises - Orlane SA - Revlon Inc. - Robanda International Inc. - Shiseido Co. - SkinMedica Inc. - Skinvisible Inc. - Woodridge Labs Inc. For more information visit http://www.researchandmarkets.com/research/76..._antiaging
How This Unique Pharma Play Keeps Winning
Brendan Mathews and Michael Douglass, The Motley Fool - Motley Fool - Mon May 19, 8:36AM CDT
Over the past five years, Valeant Pharmaceuticals ' stock is up 856%, absolutely smashing the returns delivered by the market. The company has recently made further waves by teaming up with activist investor Bill Ackman's Pershing Square Capital in...
Pershing Square Sends Open Letter Concerning Allergan's Governance Failures
Business Wire - Mon May 19, 8:02AM CDT
Pershing Square Capital Management L.P. has released an open letter sent today to the Board of Directors of Allergan, Inc. (AGN), concerning the board's governance failures with regard to its handling of Valeant Pharmaceuticals International's merger proposal. The letter, signed by Pershing Square CEO William A. Ackman, reads as follows:
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
Pfizer raises offer, highlighting flurry of deals
By The Associated Press - AP - Mon May 19, 3:25AM CDT
U.S. drugmaker Pfizer has raised its takeover bid for British rival AstraZeneca for a third time, hiking the stock-and-cash offer to nearly $119 billion (70.7 billion pounds), but AstraZeneca has quickly rejected it. The move is the latest in a flurry of proposed drug takeovers this year. The deals highlight how the global pharmaceutical industry could over time consolidate into a very small number of massive companies as competition increases from generic versions of medicines. The enhanced economies of scale could boost returns for shareholders but what it means for consumers is still unclear.
3 Things You Need to Watch at Valeant Pharmaceuticals International, Inc.
Brendan Mathews and Michael Douglass, The Motley Fool - Motley Fool - Sat May 17, 5:30PM CDT
Over the past five years, Valeant Pharmaceuticals ' stock is up 856%, absolutely smashing the returns delivered by the market. And the company has recently made waves by teaming up with activist investor Bill Ackman of Pershing Square to take...
3 Reasons Allergan Rejected Valeant: Will It Happen Anyway?
Brendan Mathews and Michael Douglass, The Motley Fool - Motley Fool - Sat May 17, 5:00PM CDT
Over the past five years, Valeant Pharmacueticals stock is up 856%, absolutely smashing the market's returns. And the company has recently made waves by teaming up with activist investor Bill Ackman of Pershing Square to take over Allergan ,...
1 Valeant Concern Investors Should Watch
Brendan Mathews and Michael Douglass, The Motley Fool - Motley Fool - Sat May 17, 3:00PM CDT
Over the past five years, Valeant Pharmacueticals stock is up 856%, absolutely smashing the returns delivered by the market. And the company has recently made waves by teaming up with activist investor Bill Ackman of Pershing Square to take over ...
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - Sat May 17, 9:51AM CDT
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S....
Data on Novo Nordisk's NovoEight - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:30PM CDT
Novo Nordisk (NVO) recently announced positive interim data from its phase III trial, Guardian 2, on NovoEight at the World Federation of Haemophilia (WFH) World Congress.
Setback for Novartis' RLX030 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:10PM CDT
Novartis (NVS) suffered a setback when the FDA issued a CRL to its Biologics License Application (BLA) for pipeline candidate RLX030 (serelaxin).
Update on Glaxo's Darapladib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:00PM CDT
GlaxoSmithKline's (GSK) darapladib performed disappointingly in a phase III study.
Legal Setback for Eli Lilly in the UK - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 3:10PM CDT
Eli Lilly (LLY) received a legal setback on Alimta in the UK.
Botox King Swings Back at "Unsustainable" Acquirer
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 16, 1:03PM CDT
Valeant Pharmaceuticals is on the hunt again, and its latest target is Botox king Allergan . Like many would-be acquisitions, Allergan isn't going down without a fight. Taking the position that Valeant's offer not only undervalues its business...
The Bellwether We've Searched For
at The Street - Fri May 16, 10:37AM CDT
You should be watching how DexCom is trading.
The Urology Care Foundation and Allergan Promote Patient Education and Advocacy at the 2014 American Urological Association Meeting
PR Newswire - Fri May 16, 7:30AM CDT
The Urology Care Foundation, the world's leading nonprofit urological health foundation and official foundation of the American Urological Association (AUA), and Allergan, Inc. (NYSE: AGN) today announced the launch of two programs at the American Urological Association Annual Meeting May 16-21 in Orlando, FL, to support the Urology Care Foundation's effort in advancing urology research and patient education.
Allergan Earnings Review: 12 Days after Announcement Shares Down 3.5% (AGN)
Comtex SmarTrend(R) - 2 hrs 12 mins ago
When Allergan (AMEX:AGN) reported earnings a week ago on May 7th, 2014, analysts, on average, expected the company to report earnings of $1.12 on sales of $1.6 billion. The company actually reported EPS of $1.18 on sales of $1.6 billion, beating EPS estimates by $0.05 and beating revenue estimates by $40.0 million. Shares of Allergan have slipped from $165.83 to $160.00, representing a loss of 3.5%, since the company reported earnings 12 days ago.
Abbott to Buy CFR Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 19, 11:00AM CDT
In a move to broaden its presence in the Latin American market, Abbott Labs (ABT) announced that it has entered into a definitive agreement to acquire CFR Pharmaceuticals.
Global Hyaluronic Acid Products Market - Forecast to 2019: Allergan, Anika and Merz dominating
PR Newswire - Mon May 19, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d98v85/hyaluronic_acid) has announced the addition of the "Global Hyaluronic Acid Products Market - Forecast to 2019: Allergan, Anika and Merz dominating" report to their offering.
AstraZeneca Rejects Pfizer's Final Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 19, 10:07AM CDT
AstraZeneca (AZN) announced that it has rejected Pfizer's (PFE) latest takeover proposal.
Global Anti-Aging Product Market 2014-2018: Beiersdorf AG, L'Oreal, Phosphagenics, Procter & Gamble & Unilever Group Dominate the Market
M2 - Mon May 19, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76jcqj/global_antiaging) has announced the addition of the "Global Anti-Aging Product Market 2014-2018" report to their offering. The analysts forecast the Global Anti-aging Product market will grow at a CAGR of 6.7% over the period 2013-2018. One of the main drivers is the rising global aging population. This growth is resulting in an increase in the need for anti-aging and age-defying facial products. Consumers are increasingly using anti-aging products made from natural and organic ingredients. Over the years, consumers have started seeking safe products and are now paying more attention to the ingredients in the anti-aging products, preferring those that do not contain chemicals or ingredients that could cause harmful side effects. Typically, anti-aging skincare and hair care products are made from synthetic ingredients, additives, and fillers. Such products could harm skin and hair, or even weaken and loosen skin when it starts aging. Natural oils such as argan, marula, coconut, and almond are some popular ingredients used in organic products. As organic products have little harmful effects, many large companies are launching natural and organic products to gain more market share. Further, the report states that one of the main challenges hindering market growth is the intensifying competition in the market caused by the entrance of new players and private labels. Key Vendors - Beiersdorf AG - L'Or?al SA - Phosphagenics Ltd. - Procter & Gamble Co. - Unilever Group Other Prominent Vendors - Allergan Inc. - Amexdrug Corp. - Avon Products Inc. - Chanel SA - Christian Dior SA - Clarins USA Inc. - DS Healthcare Group Inc. - Elizabeth Arden Inc. - Ella Bach? - Est?e Lauder Co. Inc. - Henkel AG & Co KGaA - Jan Marini Skin Research Inc. - Johnson & Johnson Co. - Kao Corp. - NeoStrata Co. - NuSKin Enterprises - Orlane SA - Revlon Inc. - Robanda International Inc. - Shiseido Co. - SkinMedica Inc. - Skinvisible Inc. - Woodridge Labs Inc. For more information visit http://www.researchandmarkets.com/research/76..._antiaging
How This Unique Pharma Play Keeps Winning
Brendan Mathews and Michael Douglass, The Motley Fool - Motley Fool - Mon May 19, 8:36AM CDT
Over the past five years, Valeant Pharmaceuticals ' stock is up 856%, absolutely smashing the returns delivered by the market. The company has recently made further waves by teaming up with activist investor Bill Ackman's Pershing Square Capital in...
Pershing Square Sends Open Letter Concerning Allergan's Governance Failures
Business Wire - Mon May 19, 8:02AM CDT
Pershing Square Capital Management L.P. has released an open letter sent today to the Board of Directors of Allergan, Inc. (AGN), concerning the board's governance failures with regard to its handling of Valeant Pharmaceuticals International's merger proposal. The letter, signed by Pershing Square CEO William A. Ackman, reads as follows:
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
Pfizer raises offer, highlighting flurry of deals
By The Associated Press - AP - Mon May 19, 3:25AM CDT
U.S. drugmaker Pfizer has raised its takeover bid for British rival AstraZeneca for a third time, hiking the stock-and-cash offer to nearly $119 billion (70.7 billion pounds), but AstraZeneca has quickly rejected it. The move is the latest in a flurry of proposed drug takeovers this year. The deals highlight how the global pharmaceutical industry could over time consolidate into a very small number of massive companies as competition increases from generic versions of medicines. The enhanced economies of scale could boost returns for shareholders but what it means for consumers is still unclear.
3 Things You Need to Watch at Valeant Pharmaceuticals International, Inc.
Brendan Mathews and Michael Douglass, The Motley Fool - Motley Fool - Sat May 17, 5:30PM CDT
Over the past five years, Valeant Pharmaceuticals ' stock is up 856%, absolutely smashing the returns delivered by the market. And the company has recently made waves by teaming up with activist investor Bill Ackman of Pershing Square to take...
3 Reasons Allergan Rejected Valeant: Will It Happen Anyway?
Brendan Mathews and Michael Douglass, The Motley Fool - Motley Fool - Sat May 17, 5:00PM CDT
Over the past five years, Valeant Pharmacueticals stock is up 856%, absolutely smashing the market's returns. And the company has recently made waves by teaming up with activist investor Bill Ackman of Pershing Square to take over Allergan ,...
1 Valeant Concern Investors Should Watch
Brendan Mathews and Michael Douglass, The Motley Fool - Motley Fool - Sat May 17, 3:00PM CDT
Over the past five years, Valeant Pharmacueticals stock is up 856%, absolutely smashing the returns delivered by the market. And the company has recently made waves by teaming up with activist investor Bill Ackman of Pershing Square to take over ...
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - Sat May 17, 9:51AM CDT
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S....
Data on Novo Nordisk's NovoEight - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:30PM CDT
Novo Nordisk (NVO) recently announced positive interim data from its phase III trial, Guardian 2, on NovoEight at the World Federation of Haemophilia (WFH) World Congress.
Setback for Novartis' RLX030 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:10PM CDT
Novartis (NVS) suffered a setback when the FDA issued a CRL to its Biologics License Application (BLA) for pipeline candidate RLX030 (serelaxin).
Update on Glaxo's Darapladib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:00PM CDT
GlaxoSmithKline's (GSK) darapladib performed disappointingly in a phase III study.
Legal Setback for Eli Lilly in the UK - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 3:10PM CDT
Eli Lilly (LLY) received a legal setback on Alimta in the UK.
Botox King Swings Back at "Unsustainable" Acquirer
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 16, 1:03PM CDT
Valeant Pharmaceuticals is on the hunt again, and its latest target is Botox king Allergan . Like many would-be acquisitions, Allergan isn't going down without a fight. Taking the position that Valeant's offer not only undervalues its business...
The Bellwether We've Searched For
at The Street - Fri May 16, 10:37AM CDT
You should be watching how DexCom is trading.
The Urology Care Foundation and Allergan Promote Patient Education and Advocacy at the 2014 American Urological Association Meeting
PR Newswire - Fri May 16, 7:30AM CDT
The Urology Care Foundation, the world's leading nonprofit urological health foundation and official foundation of the American Urological Association (AUA), and Allergan, Inc. (NYSE: AGN) today announced the launch of two programs at the American Urological Association Annual Meeting May 16-21 in Orlando, FL, to support the Urology Care Foundation's effort in advancing urology research and patient education.
